# DEA Temporary Schedule I Placement: March 16, 2026 Updates

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dea-temporary-schedule-i-placement-march-16-2026/
> **Published:** 2026-03-16T20:23:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:26-04:00
> **Clinical Summary:** Review the DEA temporary schedule I placement and regulatory updates from March 16, 2026, affecting controlled substances and cannabis clinical practice.

---

Policy WatchMarch 16, 2026. 27 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.

Score 70Federal Register

[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

Regulatory Summary

This DEA action temporarily schedules bromazolam (a benzodiazepine analog) as a controlled substance, relevant to cannabis clinicians managing concurrent sedative use and potential drug interactions with cannabinoid therapies.

[Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011)

This DEA scheduling action addresses synthetic opioids, not cannabis, and has no direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioners or patients.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013)

Regulatory Summary

This action schedules ethylphenidate as a controlled substance, which has no direct clinical relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practitioners or patients, as it addresses a different pharmaceutical compound.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0013)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001)

This regulatory action schedules synthetic opioids but does not directly affect cannabis medicine; however, clinicians should note potential drug interaction concerns when treating patients using both cannabis and scheduled substances.

[Read more →](https://www.regulations.gov/document/DEA-2024-0118-0001)

Score 70Regulations.gov
[Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001)

Regulatory Summary

DEA registration 2024-20085 authorizes pharmaceutical importation of controlled biopharmaceuticals, potentially affecting cannabis clinicians’ access to standardized cannabinoid-derived medications and research compounds.

[Read more →](https://www.regulations.gov/document/DEA-2024-0112-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003)

Regulatory Summary

The DEA temporarily placed two synthetic opioids in Schedule I, establishing legal precedent for emergency substance scheduling that cannabis clinicians should monitor regarding potential future cannabis-derived compound regulations.

[Read more →](https://www.regulations.gov/document/DEA-2023-0147-0003)

Score 70Regulations.gov
[Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001)

Regulatory Summary

The DEA proposes reclassifying marijuana from Schedule I to Schedule III, potentially enabling medical research, reducing criminal penalties, and improving patient access while maintaining federal oversight of cannabis therapeutics.

[Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001)

Score 70Regulations.gov
[Definition of Engaged in the Business as a Dealer in Firearms](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

This firearms regulation is not directly relevant to cannabis clinicians or patients, as it addresses dealer licensing requirements unrelated to cannabis medicine practice or patient care.

[Read more →](https://www.regulations.gov/document/ATF_FRDOC_0001-0052)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006)

This regulation places three synthetic opioids in Schedule I; it is not directly relevant to cannabis clinicians or patients as it concerns different controlled substances.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007)

This DEA action schedules three synthetic opioids (butonitazene, flunitazene, metodesnitazene) as controlled substances, relevant to cannabis clinicians managing pain patients who may use or consider alternative analgesics.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001)

The DEA placed 2-Methyl AP-237 in Schedule I, classifying it as a controlled substance with no accepted medical use; this action does not directly affect cannabis clinical practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001)

This regulatory action schedules synthetic amphetamines (DOI and DOC) as Schedule I controlled substances, with minimal direct relevance to cannabis medicine practice or patient care.

[Read more →](https://www.regulations.gov/document/DEA-2023-0168-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004)

Regulatory Summary

The DEA temporarily placed six synthetic cannabinoids into Schedule I, restricting their availability and establishing legal prohibitions relevant to cannabis medicine practitioners and patients seeking regulated alternatives.

[Read more →](https://www.regulations.gov/document/DEA-2023-0049-0004)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001)

Regulatory Summary

This action schedules ethylphenidate (a stimulant) as a controlled substance, establishing regulatory precedent for drug scheduling that may inform future cannabis reclassification discussions and treatment protocol considerations for clinicians.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0001)

Score 70Regulations.gov
[Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005)

This regulatory item addresses metonitazene scheduling and has no direct relevance to cannabis clinicians or patients, as metonitazene is a synthetic opioid unrelated to cannabis medicine.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0005)

Score 70Regulations.gov
[Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004)

This regulation temporarily schedules five benzodiazepine analogs as controlled substances, relevant to cannabis clinicians who may consider benzodiazepines for [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) in cannabis patients or monitor drug interactions.

[Read more →](https://www.regulations.gov/document/DEA-2022-0145-0004)

Score 70Regulations.gov
[Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001)

Regulatory Summary

This DEA application permits a biopharmaceutical research company to import controlled substances, including cannabis-derived compounds, enabling [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and development of cannabis-based medicines.

[Read more →](https://www.regulations.gov/document/DEA-2023-0096-0001)

Score 55Regulations.gov
[Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001)

Regulatory Summary

DEA permit (2024-20083) authorizes importation of controlled substances including cannabis; clinicians and patients should verify supplier DEA registration compliance for legal medication access.

[Read more →](https://www.regulations.gov/document/DEA-2024-0111-0001)

Score 55Regulations.gov
[Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001)

Regulatory Summary

DEA registration (2024-20082) permits Cambridge Isotope to import controlled substances, potentially enabling production of isotopically-labeled [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) compounds for clinical studies and therapeutic development.

[Read more →](https://www.regulations.gov/document/DEA-2024-0110-0001)

Score 55Regulations.gov
[Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045)

CMS establishes 2025 Medicare payment policies and coverage determinations for Part B services; cannabis clinicians should monitor for any coverage changes affecting cannabinoid treatments or consultation reimbursement rates.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0045)

Score 55Regulations.gov
[Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)](https://www.regulations.gov/document/CMS-2024-0256-0001)

Regulatory Summary

CMS updates 2025 Medicare Part B payment policies and coverage rules, which may affect cannabis medicine reimbursement and clinical practice standards for qualified practitioners treating Medicare beneficiaries.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0001)

Score 55Regulations.gov
[Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368](https://www.regulations.gov/document/DEA-2024-0060-0001)

Regulatory Summary

DEA approval for Royal Emerald bulk manufacturer license (2024-11786) establishes licensed cannabis production capacity, directly affecting clinician access to standardized cannabis products and patient medication availability.

[Read more →](https://www.regulations.gov/document/DEA-2024-0060-0001)

Score 55Regulations.gov
[Importer Controlled-VA Cooperative (2024-11795) DEA1374](https://www.regulations.gov/document/DEA-2024-0064-0001)

Regulatory Summary

The DEA’s Importer Controlled-VA Cooperative designation establishes import protocols for controlled substances, directly affecting cannabis clinicians’ and patients’ access to federally regulated cannabis-derived medications and research materials.

[Read more →](https://www.regulations.gov/document/DEA-2024-0064-0001)

Score 55Regulations.gov
[Importer Controlled- Quagen Pharma (2024-11892) DEA1381](https://www.regulations.gov/document/DEA-2024-0070-0001)

Regulatory Summary

DEA Form 1381 import control action for Quagen Pharma indicates monitoring of controlled substance importation procedures relevant to cannabis clinicians managing drug interactions and regulatory compliance.

[Read more →](https://www.regulations.gov/document/DEA-2024-0070-0001)

Score 55Regulations.gov
[Exempt Chemical Preparations May 2024 (2024-10465) – DEA372](https://www.regulations.gov/document/DEA-2022-0002-0006)

The DEA updated exempt chemical preparations guidance in May 2024, clarifying which cannabis-derived compounds and preparations may qualify for regulatory exemptions, affecting prescribing practices and patient access.

[Read more →](https://www.regulations.gov/document/DEA-2022-0002-0006)

Score 55Regulations.gov
[Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)](https://www.regulations.gov/document/CMS-2023-0121-22025)

This final rule establishes Medicare Part B payment policies for 2024; cannabis clinicians should monitor coverage determinations as cannabis remains federally non-covered, though state programs may reference these payment methodologies.

[Read more →](https://www.regulations.gov/document/CMS-2023-0121-22025)

Score 55Regulations.gov
[Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)](https://www.regulations.gov/document/CMS-2023-0121-0001)

This CMS regulation establishes Medicare payment policies and coverage rules for 2024; cannabis clinicians should monitor whether cannabis products gain coverage status or payment coding changes affecting patient access and reimbursement.

[Read more →](https://www.regulations.gov/document/CMS-2023-0121-0001)

Digest-Level Clinical Commentary

 Dr. Caplan’s Take
 Clinical Reflection on DEA Scheduling Activity

The predominance of synthetic opioid analogs and designer stimulants in this regulatory digest, with only item 7 directly addressing cannabis rescheduling, reflects the DEA’s current prioritization of emerging synthetic drugs of abuse over cannabis policy reform. As a cannabis medicine practitioner, this pattern suggests that federal scheduling changes for cannabis may proceed independently of broader controlled substance policy, requiring me to maintain separate clinical, legal, and regulatory frameworks for cannabis recommendations even as the opioid crisis continues to drive emergency scheduling actions. The absence of substantive cannabis-specific guidance in this particular regulatory batch underscores that evidence-based cannabis medicine will likely remain in a transitional legal space where state and federal frameworks diverge, necessitating careful documentation and patient counseling about the gap between clinical evidence and federal legal status.

 Clinical Perspective

Clinical Perspective on DEA Scheduling Actions

These notices primarily document the Drug Enforcement Administration’s systematic placement of novel synthetic opioids and designer drugs into Schedule I, reflecting an ongoing regulatory response to emerging substances of abuse that are not yet widely integrated into established treatment or medical practice. The predominance of nitazene analogs and synthetic cannabinoids in these scheduling actions suggests clinicians should remain alert to evolving drugs of abuse, particularly novel opioids that may present with unfamiliar toxidromes and limited antidote efficacy compared to traditional opioid overdoses. From a clinical standpoint, these regulatory actions serve as early warning signals that new psychoactive substances are entering the illicit market and warrant familiarity among emergency medicine and addiction medicine providers.

Controlled SubstancesDrug SchedulingDEA RegulationSynthetic DrugsCannabis Policy

💬 Join the Conversation

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Watch+%E2%80%94+March+16%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Watch+%E2%80%94+March+16%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

 Related Articles

- [This Week in Cannabis: March 16, 2026](https://cedclinic.com/cannabis-clinical-research-therapeutic-applications-march-2026/)

- [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/)

- [Oklahoma bill suggests marijuana tax to fund first responders – FourStatesHomepage.com](https://cedclinic.com/oklahoma-marijuana-tax-legislation-first-responders-funding/)

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Policy Watch: 20 Regulatory Updates — April 25, 2026](https://cedclinic.com/schedules-controlled-substances-placement-april-2026/)

Explore the latest regulatory updates following March 2026, focusing on controlled substances and cannabis policy developments.

[Read April 25 Updates](https://cedclinic.com/schedules-controlled-substances-placement-april-2026/)

[Policy Watch: 20 Regulatory Updates — June 02, 2026](https://cedclinic.com/schedules-controlled-substances-placement-june-02-2026/)

Stay current with June 2026 regulatory changes impacting controlled substances and cannabis clinical guidelines.

[Read June 02 Updates](https://cedclinic.com/schedules-controlled-substances-placement-june-02-2026/)

[Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/)

Detailed analysis of DEA's temporary scheduling of synthetic ketamine analogs relevant to clinicians monitoring controlled substance regulations.

[Explore Synthetic Ketamine Scheduling](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).